Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Danyang Sun"'
Autor:
Guangying Chen, Wushuang Du, Zhaozhen Wu, Zhichao Yue, Juan Zhang, Xuan Zheng, Yi Hu, Shixue Chen, Pengfei Cui, Jinliang Wang, Yuanyu Qian, Xiaoyan Li, Junxun Ma, Shangli Cai, Xiaochen Zhao, Danyang Sun, Chun Han, Jia Song
Publikováno v:
Journal of Clinical Oncology. 37:e14100-e14100
e14100 Background: Biliary tract cancer (BTC) is highly aggressive with poor prognosis and few treatment options following progression on gemcitabine-based chemotherapy. Disappointing results from clinical trials for refractory BTC highlight the need
Autor:
Jia Song, Yi Hu, Danyang Sun, Yuanyu Qian, Shixue Chen, Wushuang Du, Xiaoyan Li, Guangying Chen, Jinliang Wang, Pengfei Cui, Shangli Cai, Zhaozhen Wu, Xuan Zheng, Juan Zhang, Chun Han, Zhichao Yue, Junxun Ma
Publikováno v:
Journal of Clinical Oncology. 37:e14103-e14103
e14103 Background: Pancreatic cancer (PC) is a highly lethal disease and characterized by a strong resistance to current radiotherapy and chemotherapy. As PC has the presence of a microenvironment filled with immunosuppressive mediators and a dense s
Publikováno v:
Journal of Clinical Oncology. 36:148-148
148 Background: PD-1 inhibitors have shown significant clinical activity in different cancer types. However, responses in pts with NSCLC are variable, and insights are needed to identify a predictive biomarker of response with greater diagnostic accu
Autor:
Danyang Sun, Yi Hu
Publikováno v:
Journal of Clinical Oncology. 35:e15554-e15554
e15554 Background: Gastric cancer is the third leading cause of death in the world with poor prognosis. Until recently, no standard treatment was available for patients with advanced gastric cancer in the first-line setting. Nab-paclitaxel and S-1 we
Autor:
Danyang Sun, Yi Hu
Publikováno v:
Journal of Clinical Oncology. 35:e15765-e15765
e15765 Background: Pancreatic cancer is one of the highest cancer-mortality diseases worldwide with limited treatment. Most patients had local advanced or metastatic disease at the time of diagnosis. Gemcitabine-based therapy has been standard regime